Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AJ2T
|
|||
| Drug Name |
PMID28454500-Compound-13
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
REATA PHARMACEUTICALS, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H43NO5
|
|||
| Canonical SMILES |
CC1(CCC2(CCC3(C4(CCC5C(C(=O)C(=CC5(C4=CC(=O)C3(C2C1)O)C)C#N)(C)C)C)C)C(=O)OC)C
|
|||
| InChI |
1S/C32H43NO5/c1-26(2)11-13-31(25(36)38-8)14-12-30(7)29(6)10-9-20-27(3,4)24(35)19(18-33)16-28(20,5)21(29)15-23(34)32(30,37)22(31)17-26/h15-16,20,22,37H,9-14,17H2,1-8H3/t20-,22?,28-,29+,30-,31-,32+/m0/s1
|
|||
| InChIKey |
QBHNHKNDTFTWNV-BTIYJVALSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] | |
| Target's Patent Info | Cysteines of Keap1 (KEAP1 Cysteines) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.